162 related articles for article (PubMed ID: 30030357)
1. Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies.
Schwantes A; Specht R; Chen Q
PDA J Pharm Sci Technol; 2018; 72(5):498-510. PubMed ID: 30030357
[TBL] [Abstract][Full Text] [Related]
2. Proceedings of the 2017 Viral Clearance Symposium, Session 1.1: Upstream Mitigation, Part 1-Cell Bank and Bulk Harvest Testing.
Bolton G; Chen D
PDA J Pharm Sci Technol; 2018; 72(5):455-460. PubMed ID: 30030351
[TBL] [Abstract][Full Text] [Related]
3. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
4. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.
Shi L; Chen Q; Norling LA; Lau AS; Krejci S; Xu Y
Biotechnol Bioeng; 2004 Sep; 87(7):884-96. PubMed ID: 15334415
[TBL] [Abstract][Full Text] [Related]
5. A comparison of methods for the estimation of retroviral burden.
Bierley ST; Raineri R; Poiley JA; Morgan EM
Dev Biol Stand; 1996; 88():163-5. PubMed ID: 9119132
[TBL] [Abstract][Full Text] [Related]
6. Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding.
Roush D; Blümel J
PDA J Pharm Sci Technol; 2022; 76(4):323-338. PubMed ID: 34911824
[TBL] [Abstract][Full Text] [Related]
7. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
[TBL] [Abstract][Full Text] [Related]
9. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
Johnson SA; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
[TBL] [Abstract][Full Text] [Related]
10. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
[TBL] [Abstract][Full Text] [Related]
11. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
12. Multiplex RT Q-PCR assay for simultaneous quantification of three viruses used for validation of virus clearance by biopharmaceutical production.
Lute S; Wang H; Sanchez D; Barletta J; Chen Q; Brorson K
Biologicals; 2009 Oct; 37(5):331-7. PubMed ID: 19683941
[TBL] [Abstract][Full Text] [Related]
13. A novel, Q-PCR based approach to measuring endogenous retroviral clearance by capture protein A chromatography.
Zhang M; Lute S; Norling L; Hong C; Safta A; O'Connor D; Bernstein LJ; Wang H; Blank G; Brorson K; Chen Q
Biotechnol Bioeng; 2009 Apr; 102(5):1438-47. PubMed ID: 18988264
[TBL] [Abstract][Full Text] [Related]
14. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
[TBL] [Abstract][Full Text] [Related]
15. Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.
Reitz S; Schwantes A
PDA J Pharm Sci Technol; 2022; 76(4):297-305. PubMed ID: 34911829
[TBL] [Abstract][Full Text] [Related]
16. Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice--validation of virus removal and inactivation.
Trijzelaar B
Biotherapy; 1993; 6(2):93-102. PubMed ID: 8398576
[TBL] [Abstract][Full Text] [Related]
17. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
[TBL] [Abstract][Full Text] [Related]
18. Clearance of murine leukaemia virus from monoclonal antibody solution by a hydrophilic PVDF microporous membrane filter.
Aranha-Creado H; Peterson J; Huang PY
Biologicals; 1998 Jun; 26(2):167-72. PubMed ID: 9811524
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of infectivity and reverse transcriptase real-time polymerase chain reaction assays for detection of xenotropic murine leukemia virus used in virus clearance validation.
Anwaruzzaman M; Wang W; Wang E; Erfe L; Lee J; Liu S
Biologicals; 2015 Jul; 43(4):256-65. PubMed ID: 25997567
[TBL] [Abstract][Full Text] [Related]
20. Application of multivirus spike approach for viral clearance evaluation.
Valera CR; Chen JW; Xu Y
Biotechnol Bioeng; 2003 Dec; 84(6):714-22. PubMed ID: 14595784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
